London (ots/PRNewswire) - - Spontaneity and Self-Confidence Cited as Reasons Why Men Preferred Cialis In Second Study A recent analysis demonstrated that 80 percent of men who took 20 mg Cialis(R)(1) (tadalafil) for the treatment of erectile dysfunction (ED) and had successful intercourse reported ...
London (ots/PRNewswire) - - Patients with moderate-to-severe ED and comorbid conditions respond to Cialis Cialis(R)(1) (tadalafil) may effectively treat erectile dysfunction (ED) in men with a variety of comorbidities that can make the condition more difficult to manage, according to new studies released ...
Moulin International Holdings Limited
Hong Kong (ots/PRNewswire) - - Integrates the Largest Frame Manufacturer in Asia with the Most Powerful Value Proposition in the US Retail Market Moulin International Holdings Limited ("Moulin" / the "Group")(stock code: 389), a global leader in the manufacturing, distribution and retailing of eyewear, ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun. The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase III trial for its lead immunosuppressive drug candidate, ISA247. The trial will be performed over a twenty-four week period at thirty- ...
Tampere, Finland and London (ots/PRNewswire) - Inion, a rapidly growing company focused on the development of novel biodegradable medical implants, is very pleased to announce that its ordinary shares have been admitted to the Official List of the UK Listing Authority and will begin unconditional trading today on London's Main Market under the symbol IIN.L. The Company's listing in London takes place in connection ...
Basel, Switzerland, November 30 (ots/PRNewswire) - Roche and Genentech, Inc., announced today that Avastin(TM) (bevacizumab, rhuMAb-VEGF), a new innovative anti-angiogenesis drug, has shown for the first time that it significantly increases survival in patients with metastatic colorectal cancer when used in ...
Santa Fe, New Mexico, November 29 (ots/PRNewswire) - Bioreason, Inc., announced today the release of ClassPharmer(TM) Suite Lite, a new edition of the company's software system to increase success in the hits-to-leads-to-clinic process within drug discovery. ClassPharmer(TM) Suite Lite is available from ...
Laval, Quebec, November 29 (ots/PRNewswire) - LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that LAB Pharma, its drug development subsidiary headquartered in Finland, has secured approximately CAD$4.6 million (2.95 million euros) to ...
Tampere, Finland, November 26 (ots/PRNewswire) - Inion, a rapidly-growing medical device company that focuses on the development and commercialisation of novel biodegradable implants for the orthopaedic fixation market, today announces that it has successfully completed its Initial Public Offering in connection with listing on the London Stock Exchange. The shares ...
Madrid, Spain, November 25 (ots/PRNewswire) - - Aplidin(R) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in haematological malignancies, including studies in Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) ...
London, November 23 (ots/PRNewswire) - - Agfa, Vital Images, and Viatronix to Use Medicsight Software Medicsight Inc.'s (OTC Bulletin Board: MSHT) majority owned subsidiary, Medicsight PLC ("Medicsight"), announced today that it has signed letters of intent with Agfa-Gevaert N.V. and Viatronix and a ...
Seattle, November 19 (ots/PRNewswire) - Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced that it is responding to inquiries from the U.S. Attorney for the Western District of Washington in connection with previously disclosed promotional practices for TRISENOX. CTI is fully cooperating with the U.S. Attorney in this matter. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI ...
Madrid, November 19 (ots/PRNewswire) - PharmaMar announced today that Aplidin(R) (1), its second marine-derived compound in clinical development, was granted orphan drug status by the European Commission for the treatment of multiple myeloma (MM) following adoption of a positive opinion by the Committee for ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Princeton, New Jersey, November 17 (ots/PRNewswire) - Clearview Projects, Inc. announced today that Jan Wolpert has joined the company as President & CEO. Most recently, Jan was the president, founder and principal owner of Wolpert Associates, Inc., a strategic management consulting firm specializing in corporate development matters. With offices in both New Jersey and California, Clearview Projects provides ...
Montreal, November 17 (ots/PRNewswire) - - Exceptional exposure for Nstein Technologies Nstein Technologies Inc. (TSX-V: EIN), an emerging leader in new Business Intelligence (BI) solutions, received international exposure today at the United Nations at the official launch of the enhanced version of the ...
PEROS SYSTEMS TECHNOLOGIES INC
ST- NICOLAS, Canada, November 16 (ots/PRNewswire) - Under a cooperative research agreement signed in December of 2003 the USDA-ARS and PerOs Systems Technologies Inc, conducted tests combining PerOs' oral drug delivery technology, Oralject(TM), with the USDA-ARS' vaccine developed against the streptococcal ...
London, November 16 (ots/PRNewswire) - New research published today in the European Journal of Cancer (EJC) (1) indicates that an overwhelming 78 per cent of healthy premenopausal women would prefer goserelin ('Zoladex (TM)') therapy to chemotherapy if they were to develop oestrogen-receptor positive (ER+) early ...
London, November 15 (ots/PRNewswire) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' (anastrozole) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology (ASCO) Technology Assessment Panel announced a fundamental change to its internationally recognised guidance on the use of ...
Turku, Finland, November 12 (ots/PRNewswire) - - The Partnership Agreement on the First Indication (Pathological Gambling) Could be Valued at up to USD 13.2 Million Plus Royalties - Somaxon to Initiate a Phase III Clinical Development Program in Pathological Gambling Biotie Therapies Corp. and Somaxon ...
New Orleans, November 10 (ots/PRNewswire) - - Analysis of 30 Adverse Event Risk Factors Offers New Insights for Patient Care Data presented today at the 2004 American Heart Association Scientific Sessions further documented the low incidence of Major Adverse Cardiac Events (MACE) and stent thrombosis ...
Vienna, Austria, November 2 (ots/PRNewswire) - - Significant Advances in the Clinical Development of Yondelis(TM) and Aplidin(R) PharmaMar, the biopharmaceutical company specialising in cancer therapy, presented new data from its two lead drugs, Yondelis(TM) and Aplidin(R), at the 29th European Society for Medical Oncology Congress (ESMO) held in Vienna, Austria from 29 October to 2 November 2004. Data ...
London, Ontario, November 1 (ots/PRNewswire) - In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry-based publications. A convincing ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Basel, Switzerland (ots/PRNewswire) - - New Treatment Option the First to Help Postmenopausal Women With Early Breast Cancer Remain Cancer-Free Following Adjuvant Tamoxifen Therapy Femara(R) (letrozole) is the first therapy approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of postmenopausal women with early breast ...
Shire Pharmaceuticals Group Plc
St Louis, Missouri (ots/PRNewswire) - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that long-term treatment with FOSRENOL(R) (lanthanum carbonate) for up to five years, shows no deterioration in bone health according to new data presented today for the first time at the ...
Vienna, Austria (ots/PRNewswire) - - Medical experts and patients call for early diagnosis to improve chances of cure According to leading oncologists, speaking today at the European Society for Medical Oncology, findings from the MOSAIC study represent a significant step forward in providing colon ...
Madrid (ots/PRNewswire) - PharmaMar today announced that Kahalalide F (KF), its marine-origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis. KF is currently undergoing Phase II clinical trials in various tumours: melanoma, non-small lung cancer and hepatocarcinoma. During the Phase I clinical trials on ...
Madrid (ots/PRNewswire) - The Zeltia Group (ZEL.MC) today reported financial results for the third quarter and the nine months ended September 30, 2004. Q3 Highlights Financial: - Group sales up 6.3% to Euro 63.7million (Euro 59.9 million 9M03) - Losses before interest and tax narrowed significantly to Euro 2.3 million (Euro 5.5 million 9M03) - R&D down by 28.9% to Euro 27.8 million reflecting a ...